Evidence map›Paper›PMID 28384058›Full record

ArticleAIDS research and human retroviruses2017

Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States.

Iris Chen, Yinfeng Zhang, Vanessa Cummings, Gavin A Cloherty, Matthew Connor, Geetha Beauchamp, Sam Griffith, Scott Rose, Joel Gallant, Hyman M Scott and 11 more

Abstract read
In one paragraph

Article in AIDS research and human retroviruses, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. National Landscape of Human Immunodeficiency Virus-Positive Deceased Organ Donors in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  3. Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014-2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 1 country.

Iris Chen1 Bureau of Primary Health Care, Health Resources and Services Administration , Rockville, Maryland.
Yinfeng Zhang2 Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland.
Vanessa Cummings2 Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland.
Gavin A Cloherty3 Infectious Disease Research, Abbott Diagnostics , Abbott Park, Illinois.
Matthew Connor4 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington.
Geetha Beauchamp4 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington.
Sam Griffith5 Science Facilitation Department, FHI 360 , Durham, North Carolina.
Scott Rose5 Science Facilitation Department, FHI 360 , Durham, North Carolina.
Joel Gallant6 Southwest Care Center , Santa Fe, New Mexico.
Hyman M Scott7 Bridge HIV , San Francisco Department of Public Health, San Francisco, California.
Steven Shoptaw8 Department of Family Medicine, University of California Los Angeles , Los Angeles, California.
Carlos Del Rio9 Department of Global Health, Emory University Rollins School of Public Health , Atlanta, Georgia .
Irene Kuo10 Department of Epidemiology and Biostatistics, The George Washington University , Washington, District of Columbia.
Sharon Mannheimer11 Department of Medicine, Harlem Hospital, Columbia University , Mailman School of Public Health, New York, New York.
Hong-Van Tieu12 Laboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute , New York Blood Center, New York, New York.
Christopher B Hurt13 Institute for Global Health & Infectious Diseases, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.
Sheldon D Fields14 School of Health Professions, New York Institute of Technology , Old Westbury, New York.
Darrell P Wheeler15 School of Social Welfare, University at Albany, State University of New York , Albany, New York.
Kenneth H Mayer16 Fenway Health/Infectious Disease Division, The Fenway Institute , Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Beryl A Koblin12 Laboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute , New York Blood Center, New York, New York.
Susan H Eshleman2 Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland.
Fred Hutch Cancer Center · USJohns Hopkins Medicine · USNew York Blood Center · USAbbott Fund · USColumbia University · USEmory University · USGeorge Washington University · USHarvard University · USJohns Hopkins University · USSan Francisco Department of Public Health · USUniversity at Albany, State University of New York · USUniversity of California, Los Angeles · US

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
TRAINEESHIPS IN AIDS PREVENTION STUDIEST32MH019105 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carol Suzanne Camlin, Glenn-Milo Santos · 1989 to 2026
$15.3M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069470NIGMS NIH HHS T32 GM008752NIMH NIH HHS P30 MH058107NIMH NIH HHS T32 MH019105
6 · The paper itself

Abstract

Resistance to reverse transcriptase and protease inhibitors was frequently detected in HIV from black men who have sex with men (MSM) enrolled in the HIV prevention trials network (HPTN) 061 study. In this study, integrase strand transfer inhibitor (INSTI) resistance was analyzed in black MSM enrolled in HPTN 061 (134 infected at enrollment and 23 seroconverters) and a follow-up study, HPTN 073 (eight seroconverters). The ViroSeq HIV-1 Integrase Genotyping Kit (Abbott Molecular) was used for analysis. Major INSTI resistance mutations were not detected in any of the samples. HIV from 14 (8.4%) of the 165 men, including 4 (12.9%) of 31 seroconverters, had accessory or polymorphic INSTI-associated mutations. The most frequently detected mutation was E157Q. These findings are promising because INSTI-based regimens are now recommended for first-line antiretroviral treatment and because long-acting cabotegravir is being evaluated for pre-exposure prophylaxis.

Indexed as

Drug Resistance, ViralHomosexuality, MaleMutation, MissenseBlack or African AmericanBlack PeopleGenotypeGenotyping TechniquesHIV-1HIV InfectionsHIV IntegraseHumansMaleUnited StatesHIV Integrasedrug resistanceHIV integraseintegrase inhibitormen who have sex with men

Identifiers

PMID28384058
PMCPMC5512295
OpenAlexW2606316699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.